Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 6/20 | 0.56 |
| ▸ | CLK4 | Q9HAZ1 | 9/20 | 0.51 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.51 |
| ▸ | FAAH | O00519 | 2/20 | 0.41 |
| ▸ | KMO | O15229 | 1/20 | 0.39 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4452404 | 1.00 | CYP1A2 (0.56) | CYP1A2CLK4DYRK1AFAAHKMO | |
| SCHEMBL390595 | 0.81 | CYP1A2 (0.84) | CYP1A2FAAHTRPV3 | |
| SCHEMBL390596 | 0.81 | CYP1A2 (0.84) | CYP1A2FAAHTRPV3 | |
| SCHEMBL2666270 | 0.69 | KMO (0.47) | CLK4DYRK1AKMO | |
| SCHEMBL28781845 | 0.69 | EPHB4 (0.48) | CLK4DYRK1AKMO | |
| SCHEMBL2299616 | 0.68 | KMO (0.44) | CYP1A2CLK4DYRK1AKMOTRPV3 | |
| SCHEMBL3409393 | 0.68 | FAAH (0.49) | FAAH | |
| SCHEMBL390869 | 0.67 | CYP1A2 (0.71) | CYP1A2 | |
| SCHEMBL390885 | 0.67 | CYP1A2 (1.00) | CYP1A2 | |
| SCHEMBL390886 | 0.67 | CYP1A2 (1.00) | CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1808168-B1 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | ARENA PHARM INC (US) | 2009-06-03 | — | — | EP | disclosed |